A Phase 3, Multi-center, randomized, open-label study of carbavance (meropenem/rpx7009 versus best available therapy in subjects with selected serious infections due to carbapenem-resistant enterobacteriaceae
A study of subjects with serious bacterial infections using study drug
Sponsor: Rempex
Enrolling: Male and Female Patients
IRB Number: AAAO0751
U.S. Govt. ID: NCT02168946
Contact: Madeline Torres: 212-305-3727 / mt2055@columbia.edu
Additional Study Information: The purpose of this study is to test whether a study drug called Carbavance is safe and effective when compared to antibacterial medications that are commonly used for the treatment of serious infections. A screening will take 24 hours before the first dose of study drug. There are approximately 12 visits for this study.
This study is closed
Investigator
Michael Yin, MD
Do You Qualify?
Do you a diagnosis of a serious infection? Yes No
Are you allergic to penicillin-based (antibiotics) drugs? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Madeline Torres
mt2055@columbia.edu
212-305-3727
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE